Vimta Labs has received approval for foray into biologics contract research and development activities (CDMO). The estimated amount to be invested is Rs 50 crore. The foray into this new segment will help the company to enter into the growing CDMO business of biologics and peptides, that will strengthen its service portfolio to biopharmaceutical industry, enabling acceleration of its business growth. The board of directors of the company in its meeting held on April 28, 2025, has approved the same.
Vimta Labs is India’s leading contract research and testing organization.
